title: Radical prostatectomy outcomes at the University Hospital of the West Indies: 2000-2007.
abstract: OBJECTIVE
  Prostate cancer is the commonest cancer in Jamaican men with an age-specific incidence of 65.5 per 100 000 and also the commonest cause of male cancer death. This study reports on the oncological outcome and morbidity after radical retropubic prostatectomy.
  
  
  METHODS
  The records of 116 patients with clinically localized prostate cancer (cT1c- T2) who underwent radical retropubic prostatectomy at the University Hospital of the West Indies from January 2000 to December 2007 were examined. Preoperative Prostate specific antigen (PSA), clinical stage and Gleason score were recorded. Operative time, blood loss, hospital stay and complications were assessed. Oncological outcome was assessed using biochemical progression. Disease progression was defined by PSA value of 0.4 ng/ml or greater.
  
  
  RESULTS
  Mean patient age was 61 (43-75) years. The mean presenting PSA was 10.1 (2-25.1) ng/ml. Mean Gleason score on preoperative biopsy was 6. The commonest clinical stage was T1c (68%). Nodal involvement was seen in only one patient. The positive surgical margin rate was 15.5%. Mean operating time was 246 minutes and mean estimated blood loss was 1.44 L. The mean hospital stay was 6.9 days and 17% of patients developed minor complications, with no treatment or disease related deaths. Five-year biochemical-free survival was 78.4%.
  
  
  CONCLUSIONS
  Oncological outcomes after radical retropubic prostatectomy in Jamaica appear to meet global standards with acceptable morbidity.
authors.affiliation: Department of Surgery, Radiology, Anaesthesia and Intensive Care, Faculty of Medical Sciences, The University of the West Indies, Kingston 7, Jamaica, West Indies. surradic@uwimona.edu.jm
authors.forename: B F
authors.initials: BF
authors.lastname: Morrison
authors.forename: K
authors.initials: K
authors.lastname: Coard
authors.forename: G
authors.initials: G
authors.lastname: Strachan
authors.forename: R
authors.initials: R
authors.lastname: Miller
authors.forename: W
authors.initials: W
authors.lastname: Aiken
authors.forename: R
authors.initials: R
authors.lastname: Mayhew
mesh_terms: D000328:Adult; D000368:Aged; D001706:Biopsy; D016063:Blood Loss, Surgical / Q000706:statistics & numerical data; D018450:Disease Progression; D006801:Humans; D015994:Incidence; D007563:Jamaica / Q000453:epidemiology; D007902:Length of Stay / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011183:Postoperative Complications / Q000453:epidemiology; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000601:surgery*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen